Cardiovascular disease (CVD) is the first cause of mortality worldwide, with all the healthcare systems facing this very challenging issue. The World Health Organization (WHO) estimates that 31% of the world\'s deaths are due to CVD, with around 17.7 million CVD-related deaths that occurred in 2015. Approximately 7.4 million of these deaths were due to heart disease and 6.7 million deaths were due to stroke ([@B1]). More than three-quarters of CVD-related deaths occur in low- and middle-income countries. The most important risk factors for heart disease and stroke are unhealthy diet, physical inactivity, tobacco and alcohol use, which lead to high blood pressure, sugar, fat, overweight and obesity ([@B2]). Platelet activation plays an important role in the development of CVD. Antiplatelet therapy prevents platelet aggregation and thrombosis, and can be used in primary and secondary prevention of CVD ([@B3]). Despite the development of next-generation drugs, aspirin continues to be the major gold-standard treatment worldwide in the prevention of thrombotic disease in patients with CVD ([@B4]).

From a biochemical standpoint, aspirin inhibits the conversion of arachidonic acid to thromboxane A2, the main metabolite of prostaglandin synthesis, *via* cyclooxygenase (COX) ([@B5]). Even low daily aspirin doses (in the range 75-150 mg) are able to suppress biosynthesis of thromboxane, inhibiting the accumulation of platelets, and reducing the risk of CVD ([@B6]). However, aspirin does not always prevent the formation of thromboxane A2 due to failure to inhibit platelet COX ([@B7]). As such, all individuals do not respond to antiplatelet therapy in a similar way; some people suffer from thromboembolic events despite ongoing antiplatelet therapy ([@B8], [@B9]). The mechanism of resistance to aspirin is still unclear. Different patients may require different doses of aspirin to inhibit platelet function ([@B10]) and this calls up for a personalized treatment.

Several studies have been conducted to evaluate the rate of resistance to aspirin in CVD patients. Therefore, the aim of this study was to determine the prevalence of aspirin resistance by conducting a systematic review and meta-analysis of aspirin resistance in CVD patients worldwide.

Methods
=======

The research question of the present work is the worldwide prevalence rate of laboratory defined aspirin resistance in CVD patients. This is a systematic review and meta-analysis that identified aspirin resistance studies with an assessment of its adverse effects on cardiovascular patients. There are several measurement methods to investigate platelet function test, Findings showed that the blood test is more sensitive than urine level, therefore, the present study mostly used two methods of platelet function test and verify now aspirin assay, Some studies also used platelet aggregation multiple method ([@B11]). Findings of this study were reported on the basis of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses"(PRISMA) guidelines ([@B12]). We searched different scholarly electronic databases, such as EMBASE, PUBMED/MEDLINE, ISI/Web of Science, Scopus, and the Cochrane Library, from January 2000 to February 2018. To find more potentially relevant studies, the reference list of the included studies was also hand-searched. After the search, all records were entered to the EndNote Reference Manager X8. At this point, all duplicate articles were deleted. Using the Boolean operators (AND, OR), the search strategy was performed as follows: ("platelet resistance" OR "drug resistance" OR "acetylsalicylic acid" OR aspirin OR "antiplatelet platelets" OR "aspirin resistance") AND ("cardiovascular disease" OR "ischemic heart disease" OR **"**acute coronary syndrome**"**). A total of 2047 studies were reached from databases search, after deletion of the number 650 duplicates, 987 unrelated studies and 204 articles on the base abstract were excluded, 138 studies were included to title and abstract screening. In addition, we found 32 studies based on other sources. A total of 138 studies full texts were resumed and reviewed based on inclusion criteria. Finally, 65 studies with 10,729 participants were subjected.

Studies were included if: i) designed as cross-sectional, cohort or case-control investigations; ii) studies whose data were appropriate for the calculation of the prevalence rate; iii) patients with a proper clinically established diagnosis of CVD; and iv) peer reviewed studies published in English. Studies were excluded if: i) designed as letters to editor, editorials, commentaries, case reports or case series and reviews; ii) overlapping studies (in case of repeated/ duplicate/redundant studies, the most comprehensive ones were selected); iii) studies whose data did not allow the calculation of the prevalence rate; and iv) studies whose full-text could not be accessed

Two of the authors independently selected the studies on the basis of these criteria, and in case of disagreement, a third person was used as the referee and eventually resolved the issue through discussion.

**Data extraction:**After selecting the studies, two authors independently extracted and collected the data from the included studies: namely, the surname of the first author of the article, year of publication, country of study, number of participants in the study (based on gender, if available), type of laboratory-defined aspirin resistance,  prevalence rate, and mean age or age range of participants. Before analysis we certified the precision of the data. We revised any unequal data and adjusted accordingly.

**Assessment of methodological quality:**The methodological quality of the included studies was critically appraised using the Newcastle-Ottawa (NOS) scale ([@B13]). Three, two and five stars were assigned to the scale items based on the three domains (selection of study participants, control of confounders and outcome of interest), respectively. Based on the overall score, studies were divided into three groups: high (1-4 stars), medium (5-7 stars) and low (8-10 stars) bias.

**Statistical analysis:**The pooled prevalence of laboratory-defined aspirin resistance was computed using the Der Simonian-Laird random-effect model with its 95% confidence interval (CI) ([@B14]). To calculate the effect size (ES), the total sample size and the number of laboratory-defined aspirin resistance patients were used. The I^2^ test was used to evaluate heterogeneity between studies, which was classified as low, moderate and high (25%, 50% and 75%, respectively) ([@B15]). To assess, the role of variables such as sample size, or geographic area of studies was conducted. To ensure the stability of the results and to investigate the impact of each study on the final outcome, a sensitivity analysis was performed. To examine the effect of gender in laboratory-defined aspirin resistance, odds ratio (OR) was calculated. Also, studies were ranked based on the year of publication and cumulative meta-analysis was conducted to examine the trend of changes over time. Visual inspection of the funnel plot and Egger's regression test were used to evaluate the publication bias ([@B16]). Figures with p\<0.05 were considered statistically significant. All statistical analyses were conducted with the commercial software comprehensive meta-analysis (CMA) Version 2.

Results
=======

After the initial search of the databases, out of a list of 2079 items, 65 studies were included and analyzed based on the above-mentioned inclusion/exclusion criteria (figure 1) (17-[@B81]). The overall number of CVD patients was 10,729. [Appendix 1](#T1){ref-type="table"} shows the characteristics of the studies retained in the current systematic review and meta-analysis.
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###### 

The characteristics of the studies

  **Author**      **Year**   **Country**      **Sample size**   **Male**   **Female**   **ER**   **LL**   **UL**   **QOS**
  --------------- ---------- ---------------- ----------------- ---------- ------------ -------- -------- -------- ---------
  Aksu            2014       Turkey           203               128        75           0.300    0.241    0.367    10
  Akturk          2014       Turkey           134               126        19           0.164    0.111    0.237    8
  Abid            2012       Tunisie          79                38         35           0.241    0.159    0.347    10
  Abaci           2005       Turkey           184               96         88           0.152    0.107    0.212    10
  Aksu            2009       Turkey           220               161        59           0.382    0.320    0.448    10
  arslan          2015       Turkey           50                34         16           0.320    0.206    0.460    8
  Aydinalp        2008       Turkey           338               168        170          0.240    0.197    0.288    8
  Bach            2009       Germany          42                30         12           0.143    0.066    0.283    10
  Blann           2012       UK               169               138        31           0.290    0.227    0.363    10
  Çagirci         2009       Turkey           32                23         9            0.339    0.232    0.464    9
  Cagirci         2010       Turkey           44                34         10           0.477    0.336    0.623    8
  Acikel          2009       Turkey           97                65         32           0.299    0.216    0.397    8
  Cao             2016       China            1130              872        258          0.503    0.474    0.532    10
  Cao             2012       China            304               NA         NA           0.204    0.162    0.253    9
  Catakoglu       2009       Turkey           100               77         23           0.140    0.085    0.223    8
  Cetin           2014       Turkey           70                28         42           0.371    0.267    0.490    8
  Chadha          2016       Indian           126               100        26           0.357    0.278    0.444    8
  Chakroun        2007       Tunisia          191               172        19           0.157    0.112    0.216    8
  Chen            2007       China            468               323        145          0.274    0.235    0.316    9
  Chen            2005       China            117               88         29           0.188    0.127    0.269    10
  Chen            2004       China            151               114        37           0.192    0.137    0.263    9
  Cheng           2007       China            54                34         20           0.296    0.190    0.430    9
  Christiaens     2002       France           50                44         6            0.200    0.111    0.333    8
  Christiaens     2008       France           97                76         21           0.299    0.216    0.397    10
  Chu             2010       New Zealand      314               162        152          0.477    0.336    0.623    10
  Crowe           2005       Ireland          31                25         6            0.419    0.261    0.596    10
  Cuisset         2009       France           136               102        34           0.014    0.091    0.209    10
  Doly            2016       France           64                44         20           0.141    0.75     0.249    10
  Dorsch          2007       North Carolina   94                28         66           0.298    0.214    0.398    10
  Durmaz          2008       Ankara           69                54         15           0.261    o.o71    0.377    7
  Floyd           2014       UK               93                32         61           0.183    0.117    0.275    10
  Foussas         2009       Greece           469               344        125          0.258    0.220    0.300    10
  Glauser         2009       USA              200               101        99           0.065    0.038    0.109    9
  Golanski        2004       Poland.          24                24         0            0.167    0.064    0.369    8
  Grove           2010       Denmark          64                49         15           0.125    0.064    0.231    9
  Hiyasat         2012       Germany.         100               NA         NA           0.750    0.656    0.825    10
  Hobikoglu       2005       Turkey           204               148        56           0.338    0.277    0.406    10
  Hobikoglu       2005       Turkey           100               72         28           0.270    0.192    0.365    10
  Ibrahim         2013       Malaysia         74                63         11           0.162    0.094    0.264    10
  Kim             2011       Korea            220               162        58           o.109    0.050    0.222    10
  Kim             2010       Korea            55                NA         NA           0.177    0.132    0.233    10
  Kranzoeer       2006       Germany          55                NA         NA           0.455    0.329    0.586    8
  Liu             2013       China            246               167        79           0.248    0.198    0.306    8
  Lopez-Farre     2006       Spain            38                15         4            0.500    0.346    0.654    8
  Lordkipanidze   2007       Canada           201               155        46           0.597    0.528    0.663    10
  Macchi          2002       France           72                55         17           0.292    0.199    0.406    10
  Manica          2012       USA              108               58         50           0.065    0.031    0.130    7
  Marcucci        2006       Italy            147               116        31           0.299    0.231    0.378    10
  Mirkhel         2006       USA              123               64         64           0.081    0.044    0.145    7
  Narvaez         2007       Spain            268               185        83           0.164    0.124    0.213    10
  Ozben           2010       Turkey           200               111        89           0.210    0.159    0.272    10
  Pamukcu         2006       Turkey           234               182        52           0.190    0.126    0.277    8
  Pamukcu         2007       Turkey           505               382        123          0.234    0.199    0.273    9
  Poston          2005       American         225               127        98           0.298    0.242    0.361    10
  Salama          2012       Egypt            50                40         10           0.220    0.126    0.355    9
  Schwartz        2008       USA              184               115        69           0.038    0.018    0.078    10
  Serdar          2013       Turkey           100               65         35           0.220    0.149    0.312    8
  Stejskal        2006       Czech            103               66         37           0.447    0.354    0.543    10
  Stolarek        2015       Poland           194               150        44           0.062    0.035    0.106    10
  Tantry          2005       USA              223               131        92           0.090    0.059    0.135    10
  Vivas           2011       USA              141               123        18           0.504    0.422    0.585    7
  Wang            2011       UK               111               80         31           0.297    o.220    0.389    10
  Ziaee           2004       IRAN             170               91         79           0.753    0.683    0.812    9
  Angiolillo      2006       Italy            105               82         23           0.444    0.363    0.529    9
  Pamukcu         2007       Turkey           234               182        52           0.222    0.174    0.280    9

E R =Event rate

L L=Lower limit

U L=Upper limit

Q O S=Quality of score

**Pooled prevalence of** **aspirin resistance in patients with cardiovascular disease:**The overall prevalence of aspirin resistance in CVD patients was 24.7% (\[95%CI 21.4-28.4\], I^2^=93.89%, p\<0.001; [Figure 2](#F1){ref-type="fig"}).
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**Results of subgroup analysis:**Based on sample size, geographic regions, year of study publication, quality of studies and gender of participants, the results of the different subgroup-analyses are shown in table 1.

**Prevalence of aspirin resistance and sample size:**Based on the sample size, the prevalence of aspirin resistance reported in 39 studies with up to 150 participants was 26.4% \[95%CI 22.2-31\], compared to 22.5% \[95%CI 21.6-28.6\], reported by 26 studies with more than 150 participants. This difference was not statistically significant (p=0.47).

**Prevalence of aspirin resistance and** **geographical background:**According to the geographic region, the prevalence in Asia was reported by 11 studies and was 27.3% \[95%CI 22.4-29.4%\], while the rate in Europe was available in 41 studies (25.7%, \[95%CI 22.4-29.4%\]). In Africa, a prevalence of 19.5% \[95%CI 16.2-25.5\] was found, whereas in America was of 19.1% \[95%CI 10.2-32.2\]. The difference in prevalence rate broken down to geographic background was statistically significant (p\<0.0001).

**Prevalence of aspirin resistance and** **year of publication:**Between 2000 and 2006, 17 studies reported a prevalence rate of 25% \[95%CI 19.7-31.2\], whereas between 2007 and 2012, the prevalence was 24.5% \[95%CI 20.2-29.2\] according to 34 studies. Finally, in the years 2013-2017, the prevalence was 24.8% \[95%CI 16.9-34.9\]. From a statistical standpoint, the prevalence rate of aspirin resistance among CVD patients was not significant on the basis of the years of study (p=0.63).

**Prevalence of aspirin resistance and** **quality of studies:**Based on the checklist used to evaluate the quality of the studies, 5 studies with a score of 4 to 7 reported a prevalence of 42.9% \[95%CI 28.9-59.1\], whereas in 60 studies with a score of 8 to 10, the prevalence was 23.5% \[95%CI 17.5-26.7\], although this difference was not statistically significant (p=0.15).

**Prevalence of aspirin resistance and** **gender:**In 39 studies, data were suitable for calculating the prevalence of laboratory-defined aspirin resistance stratified according to gender. More in details, the prevalence in men was 23.5% \[95%CI 19.5-28.0\] and in women 26.9% \[95%CI 22.4-31.9\]. This difference was statistically significant (p\<0.0001). An OR of 1.16 \[95%CI 0.87-1.54\] was computed (figure 3). This finding showed that women are at increased risk of laboratory-defined aspirin resistance compared to men.

**Results of cumulative meta-analysis** **for the** **prevalence ofin patients with cardiovascular disease:**The studies were ranked according to the year of publication and cumulative meta-analysis was performed. The results did not change before and after this analysis, and the prevalence was 24.7% \[95%CI 21.4-28.4\]. Appendix 2 shows cumulative meta-analysis based on the year of publication. Studies were also ranked by sample size. The results did not change before and after the cumulative meta-analysis and the prevalence was stable. Appendix 3 shows cumulative meta-analysis based on the year of publication.

**Results of sensitivity analysis** **for the** **prevalence ofaspirin resistance in patients with cardiovascular disease:**Sensitivity analysis was carried out to ensure the stability of the results of the studies. The prevalence of aspirin resistance before and after the sensitivity analysis did not change with the exclusion of each study (Appendix 4).

**Publication bias:**The Egger's regression test results are presented in [Appendix 5](#F2){ref-type="fig"}. Observation of the asymmetry of the funnel plot indicated that there was an evidence of publication bias (p=0.38).
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Discussion
==========

The aim of this study was to determine the prevalence rate of laboratory defined aspirin resistance in CVD patients worldwide. The concept laboratory defined aspirin resistance has been argued since 1980s, but discussions in late literature have centralized on evidence why aspirin resistance is probably a mistake ([@B82], [@B83]). To the best of our knowledge, systematic search of the literature, meta-analysis and extensive statistical analyses (sub-group analysis, sensitivity analysis, cumulative meta-analysis) were the major strengths of this study. The findings showed that the prevalence of laboratory-defined aspirin resistance in CVD patients was 24.7%, with a higher rate among women. This study, pooling together different investigations reporting conflicting results, has enabled to overcome their statistical limitations and shortcomings. Some studies have, indeed, found that women have more or equal responsiveness rate to aspirin than men, being successful in controlling the COX-1 pathway, whilst other studies have shown no difference between female and male ([@B7]). According to other scholars, women would have a worse prognosis than men, whereas other studies reported that the biochemical mechanism of laboratory-defined aspirin resistance is unknown, even though female sex hormones may play an important role ([@B84], [@B85]). We computed an OR of 1.16 \[95%CI 0.87-1.54\], showing that women are at increased risk of laboratory-defined aspirin resistance compared to men.

Another important finding of the study is that, the prevalence rate is different in different regions of the world, putatively because of differences in the biological and genetic make-up of individuals. A higher prevalence was found in Asia, while the lowest rate was computed for studies carried out in America.

These findings pave the way for a personalized treatment, in that individual factors seem to affect the response to aspirin. Clinically speaking, there are some conditions known for predisposing patients to higher rate of aspirin resistance. For instance, several studies have shown that patients undergoing coronary artery bypass grafting (CABG), which results in endothelial tissue damage to the saphenous vein graft, or coronary interventions, are more likely to become resistant to aspirin, with high thrombin level and platelet activation ([@B10], [@B86]). This suggests that, after CABG surgery or other interventions, patients should be closely monitored and should receive plavix, alternatively, anti-thrombotic drugs. Usually, aspirin resistance after a CABG surgery persists for a short term period ([@B22], [@B87]). This temporal laboratory-defined aspirin resistance was in a population of patients who had withstand coronary bypass. Although no adaptation with treatment is a momentous cause of laboratory aspirin resistance, patient dependency treatment was determined in few studies ([@B88]-[@B90]). Cotter et al, have indicated no adaptation to treatment is a significant moderator of negligible consequence. It is substantial to appraise whether patients take their medicines in clinical conditions or in studies that measure the effect of prescription drugs ([@B89], [@B90]). According to research, another strategy to control laboratory defined aspirin resistance is the administration of vitamin D ([@B91]). Furthermore, patients not practicing enough physical activity and/or with increased blood glucose should require higher aspirin doses ([@B92], [@B93]).

However, despite its strengths, the present systematic review and meta-analysis suffers from some limitations, that hinder generalization of the present findings and call up for caution in interpreting results. The major drawback is given by the heterogeneity between studies and the evidence of publication bias. Another limitation is given by the methodological and quality differences among the studies. As such, further larger high-qualities studies in the field are warranted. Moreover, available study data did not allow to investigate the impact of possible risk factors associated with the prevalence of laboratory-defined aspirin resistance.

The findings of the present systematic review and meta-analysis showed that the prevalence of laboratory defined aspirin resistance in CVD patients was 24.7%. Doctors and healthcare providers should pay special attention to this, since lack of awareness could cause problems and increase mortality in these patients, if not properly treated with higher aspirin doses. It is suggested that one way to overcome the problem of laboratory defined aspirin resistance perhaps is to give the patient more medicine. However, this cannot be the result of the study, and more specific studies are required, in the way that the method of platelet related assay, the length of treatment and the amount of drug in patient have the same conditions.
